HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

Published online before print December 23, 2004

This Article Full Text (Reprint (PDF)) All Versions of this Article: jlb.0904558v1 77/3/281    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schwarz, H. Search for Related Content PubMed PubMed Citation Articles by Schwarz, H.

© by The Society for Leukocyte Biology
Journal of Leukocyte Biology, doi:10.1189/jlb.0904558

Received for publication September 27, 2004.
Revised November 9, 2004.
Accepted for publication November 11, 2004.

Article

Biological activities of reverse signal transduction through CD137 ligand

Department of Physiology, National University of Singapore

	Abstract

CD137 is a member of the tumor necrosis factor receptor family and a potent regulator of T cell activities. Agonists of CD137 have been used widely and successfully to treat cancer in animal models, and recently, it has become evident that CD137 agonists can also be used to treat autoimmune disease. An aspect of the CD137 receptor/ligand system, which has been comparatively little-explored, is its ability of reverse signaling. Just as is CD137, the CD137 ligand is also expressed as a cell membrane protein, and it too can transduce signals into the cells on which it is expressed. This bidirectional signaling capacity allows the CD137 receptor/ligand system to mediate extensive cross-talk between immune cells and between immune and nonimmune cells. This review summarizes the known activities of the CD137 ligand on the different leukocyte subsets and on cancer cells and discusses their influence on the course of immune responses.

Key Words: TNF superfamily family • reverse signaling • bidirectional signal transduction

This article has been cited by other articles:

				D. Jiang, Y. Chen, and H. Schwarz CD137 Induces Proliferation of Murine Hematopoietic Progenitor Cells and Differentiation to Macrophages J. Immunol., September 15, 2008; 181(6): 3923 - 3932. [Abstract] [Full Text] [PDF]

				D. Jiang, P. S. E. Yue, D. Drenkard, and H. Schwarz Induction of Proliferation and Monocytic Differentiation of Human CD34+ Cells by CD137 Ligand Signaling Stem Cells, September 1, 2008; 26(9): 2372 - 2381. [Abstract] [Full Text] [PDF]

				M. Sun and P. J. Fink A New Class of Reverse Signaling Costimulators Belongs to the TNF Family J. Immunol., October 1, 2007; 179(7): 4307 - 4312. [Abstract] [Full Text] [PDF]

				Y. Yang, S. Yang, Z. Ye, J. Jaffar, Y. Zhou, E. Cutter, A. Lieber, I. Hellstrom, and K. E. Hellstrom Tumor Cells Expressing Anti-CD137 scFv Induce a Tumor-Destructive Environment Cancer Res., March 1, 2007; 67(5): 2339 - 2344. [Abstract] [Full Text] [PDF]

				D. Drenkard, F. M. Becke, J. Langstein, T. Spruss, L. A. Kunz-Schughart, T. E. Tan, Y. C. Lim, and H. Schwarz CD137 is expressed on blood vessel walls at sites of inflammation and enhances monocyte migratory activity FASEB J, February 1, 2007; 21(2): 456 - 463. [Abstract] [Full Text] [PDF]

				S.-W. Lee, A. T. Vella, B. S. Kwon, and M. Croft Enhanced CD4 T Cell Responsiveness in the Absence of 4-1BB J. Immunol., June 1, 2005; 174(11): 6803 - 6808. [Abstract] [Full Text] [PDF]